AVANCE CLINICAL IS RECOGNIZED AS A
2026 COMPANY OF THE YEAR
Frost & Sullivan has identified the company as demonstrating best practices within the biotechnology contract research organization industry.
What You Need to Know about the Company of the Year Recognition
Frost & Sullivan’s Company of the Year is its top honor and recognizes the market participant that exemplifies visionary innovation, market-leading performance, and unmatched customer care.
For the Company of the Year Recognition, Frost & Sullivan analysts independently evaluated the criteria listed below.
“Frost & Sullivan commends Avance Clinical for building continuity into delivery, communication, and leadership access from the outset. This operating structure gives biotech sponsors a more aligned and dependable CRO in a market that places high value on strategic fit, transparency, and execution quality.”
- Unmesh Lal Vice President, Healthcare
“Frost & Sullivan observes that Avance Clinical adds depth in areas where biotech sponsors face greater complexity and where specialized expertise improves program execution and later-phase readiness. This growth strengthens the company’s position and relevance to sponsors that require stronger therapeutic support across clinical development.”
- Ain Sarah Aishah Best Practices Research Analyst
Avance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership
The company is recognized for its innovation, scientific expertise, and customer-centric clinical development model in the global biotechnology CRO market.